Pancreatic Cancer Research

ResearcherKochi Health Sciences CenterActive in the last 2 years

Kenta Sui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-5441-6005; OpenAlex author ID A5042701108. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Co-author DOI 10.3390/cancers18071181↗
  2. Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Co-author DOI 10.3390/cancers17223694↗
  3. Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. First author DOI 10.3390/jcm11226792↗
  4. A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-021-02167-z↗
  5. Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients. Co-author DOI 10.1016/j.amjsurg.2019.04.014↗
  6. A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6485-7↗
  7. Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. Co-author DOI 10.1259/bjr.20170165↗
  8. [A case of a patient who underwent resection of the remnant pancreatic cancer following a distal pancreatectomy for invasive ductal carcinoma]. Co-author PMID 25731457↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takehiro Okabayashi MD · 7 shared papers, 2017–2026 · strength 1.02
  2. Toshiyoshi Fujiwara · 3 shared papers, 2022–2026 · strength 0.61
  3. Jun Iwata · 5 shared papers, 2017–2022 · strength 0.56
  4. Yasuhiro Shimada · 5 shared papers, 2017–2022 · strength 0.56
  5. Kazuya Yasui · 2 shared papers, 2025–2026 · strength 0.46
  6. Kosei Takagi · 2 shared papers, 2025–2026 · strength 0.46
  7. Ryuichi Yoshida · 2 shared papers, 2025–2026 · strength 0.46
  8. Tatsuo Iiyama · 4 shared papers, 2017–2022 · strength 0.43
  9. Takatsugu Matsumoto · 2 shared papers, 2020–2021 · strength 0.27
  10. Yasuo Shima · 2 shared papers, 2017–2018 · strength 0.15
  11. Tatsuaki Sumiyoshi · 2 shared papers, 2017–2018 · strength 0.15
  12. Keiichi Kubota · 1 shared paper, 2021 · strength 0.13
  13. Akihito Nishioka · 1 shared paper, 2017 · strength 0.06
  14. Manabu Matsumoto · 1 shared paper, 2017 · strength 0.06
  15. Tetsushige Mimura · 1 shared paper, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.